photo of woman looking at medical bills

Ulcerative colitis is an inflammatory bowel disease (IBD) that causes inflammation and ulcers in the colon. Traditional medications can help control the disease. But if your symptoms are moderate or severe, or if other treatments stop working, your doctor may recommend biologic therapies, which usually cost more.

What Are Biologics?

Biologic treatments are made from living cells. Unlike other medications, they work by blocking specific proteins that cause intestinal inflammation. This helps lower inflammation and control symptoms.

Here are some of the most commonly used biologics to treat ulcerative colitis:

Tumor necrosis factor inhibitors (anti-TNFs). These medications control intestinal inflammation by blocking an immune system protein known as tumor necrosis factor.

They are usually prescribed to people who have tried other medications without getting the desired results or who have had uncomfortable side effects with other treatments.

  • Adalimumab (Humira)
  • Golimumab (Simponi)
  • Infliximab (Remicade)

Integrin receptor antagonists. These medications control inflammation by preventing inflammatory cells from entering intestinal tissue. The one used to treat UC is vedolizumab (Entyvio).

Interleukin-23 antagonists. These medications are monoclonal antibodies that target the protein interleukin-23 (IL-23).

  • Guselkumab (Tremfya)
  • Mirikizumab (Omvoh)
  • Risankizumab (Skyrizi)

Interleukin-12 and -23 antagonist. Ustekinumab (Stelara) is a monoclonal antibody that blocks the proteins IL-12 and IL-23, which cause inflammation in the body.

The FDA also approved ustekinumab (Stelara) to treat moderate to severe ulcerative colitis in children ages 2 and older.

If you have questions about specific medications for UC, you should talk to your doctor. The Crohn’s and Colitis Foundation has also created a helpful online tool that can help answer your questions between appointments.

Cost of Biologics for Ulcerative Colitis

The cost of biologic treatments for ulcerative colitis can vary greatly and can increase over time for several reasons:

  • Nearly half of the people with ulcerative colitis need to be hospitalized at some point, which can significantly increase health care costs.
  • Recent studies show that for a person with moderate to severe ulcerative colitis, the average cost of the first year of advanced therapy, which includes biologics, is over $42,579.
  • It is estimated that medications make up most of the treatment expenses, between 63% and 90% of the total cost per person.
  • Over a lifetime, up to 30% of those diagnosed may need at least one surgery related to their condition.

Health Insurance Coverage for Biologics

Most health insurances cover biologic therapies, including private plans, Medicare, and Medicaid. Your individual plan details determine how much you pay out of pocket and when you can start treatment.

Insurance usually covers biologics when:

  • Ulcerative colitis is moderate or severe.
  • Other treatments haven't worked.
  • The biologic is approved by the FDA.
  • Your doctor gets prior authorization, which involves sending paperwork to show the treatment is necessary.
  • Step therapy requirements are met, meaning you've tried other treatments first.

How and where you get your treatment also affect costs. The way you receive your biologic can impact how much you pay and how much counts towards your deductible.

In general:

  • Intravenous (IV) infusions are covered as a medical benefit by your insurance, which applies to treatments given at a healthcare facility.
  • Shots you give yourself at home are usually covered as a pharmacy benefit, which includes medications you get at a pharmacy or specialty pharmacy.

Copays, Coinsurance, and Deductibles for Biologics

Even if your insurance covers the medication, you might still have to pay a large part out of pocket. This happens when your plan has a high deductible or high coinsurance. That's why it's important to carefully review the details of your policy and confirm them directly with your insurance.

Copay: This is a fixed amount you pay each time you receive treatment, like an infusion or a prescription.

Coinsurance: This is a percentage of the total cost of the medication you must pay. If the treatment is expensive, that amount can be high.

Deductible: This is the amount you must pay before the insurance starts covering most of the costs.

Biosimilars: A More Accessible Option?

Biosimilars are medications made from living organisms, similar to original biologics, and they can be a more accessible option. They are approved by the FDA.

In general:

  • Biosimilars usually cost less because they follow a different approval process than original biologics.
  • They encourage market competition, allowing insurance plans to negotiate better prices and prioritize their coverage.
  • They can lower costs, as you pay less in copays and coinsurance and it's easier for your insurance to approve these medications.

How Does Ulcerative Colitis Affect the Hispanic Community?

For many families, the challenges they face affect both their health and their finances. These difficulties are often felt more strongly in the Hispanic community due to gaps in coverage and barriers to accessing health care.

In general:

  • Hispanic people with ulcerative colitis face more obstacles to accessing medical care, such as insufficient coverage, limited job options, or language barriers.
  • The Hispanic community has higher rates of hospitalization and mortality, even though the disease is not more common than in other groups.
  • Medical costs can be higher, with average yearly expenses of $63,349 per person, compared to $38,240 for other groups.

Tips for Managing and Preparing for the Costs of Treatment

Before starting any treatment, it's a good idea to talk with your doctor and your insurance company to understand your costs and make informed decisions. You should:

  • Ask if the biologic is covered as a medical benefit or a pharmacy benefit, as this difference can affect how much you pay and how much counts towards your deductible. 
  • Check how your deductible, coinsurance, copays, and out-of-pocket maximum work.
  • Learn about prior authorizations and step therapy, and find out what paperwork is needed and how long approval usually takes.
  • Keep a simple record of your treatment and expenses, including dates of your infusions or prescriptions, calls to your insurance, letters received, and amounts paid.
  • Explore financial assistance options from the start of treatment, rather than waiting until costs become hard to manage.
  • Look for manufacturer support programs when available, such as copay cards, assistance programs, and help coordinating benefits.
  • Ask for help if your insurance denies coverage. Your doctor's office can help you file appeals and handle prior authorizations and medical paperwork.

When Is It Time to Switch to Another Treatment?

If you have moderate to severe ulcerative colitis, having several biologic options allows you to adjust your treatment over time to better control your symptoms.

Consider making a change when:

  • Symptoms persist or return despite treatment.
  • The treatment doesn't work as expected, which can lead to more doctor appointment, ER visits, or hospitalizations.
  • Costs increase due to not responding to the current medication.
  • You find an alternative that better suits your needs after talking to your gastroenterologist about other options.

Show Sources

Photo Credit: iStock/Getty Images

SOURCES:

Mayo Clinic: "Ulcerative colitis."

Cleveland Clinic: "Ulcerative Colitis."

National Library of Medicine: "Ulcerative Colitis: Advances in Pathogenesis, Biomarkers, and Therapeutic Strategies," "Patient-Reported Racial and Ethnic Disparities in Patients With Ulcerative Colitis: Results From the National Health and Wellness Survey," "Cost Comparison Table of Biologics for the Treatment of Crohn’s Disease," "Effect of Biologic Therapies in Treating Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis," "Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis."

Crohn’s & Colitis 360: "Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib," "Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis."

Crohn’s & Colitis Foundation: "Managing the Cost of IBD," "Patient Financial Assistance Programs," "Understanding Health Insurance."

gastro.org: "Living guideline for pharmacological management of moderate-to-severe ulcerative colitis," "Ulcerative Colitis."

CMS.gov: "Health care terms, medical bills, and forms can be hard to understand. Here are some common health care terms, and what they mean."

FDA: "Biosimilars Basics for Patients," "Biosimilar and Interchangeable Biologics: More Treatment Choices."

American College of Gastroenterology: "Ulcerative Colitis."